Effective tumor-targeted delivery of etoposide using chitosan nanoparticles conjugated with folic acid and sulfobetaine methacrylate. Issue 94 (23rd September 2016)

• Record Type: Journal Article
• Authors: Hua, Song; Yu, Jiahua; Shang, Jun; Zhang, Haowen; Du, Jie; Zhang, Yushuo; Chen, Fei; Zhou, Yuan; Liu, Fenju
• Is Part Of: RSC advances. Volume 6:Issue 94(2016)
• Page Start: 91192
• Page End: 91200
• Publication Date: 2016-09-23
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/c6ra14104h
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : FA–CS(VP-16)- g -PSBMA nanoparticles were synthesized and showed effective tumor-targeting properties and promising anti-tumor capacity in vivo . Abstract : We demonstrated chitosan (CS)-based biocompatible nanoparticles coated with folic acid (FA) and poly(sulfobetaine methacrylate) (PSBMA) as an effective tumor-specific drug delivery system. The graft copolymer FA–CS- g -PSBMA could self-assemble into nanoparticles in an aqueous phase and maintain a spherical shape. Etoposide (VP-16), a widely-used chemotherapy drug with poor water solubility, could be incorporated into the inner core of hydrophobic CS to form FA–CS(VP-16)- g -PSBMA nanoparticles. The synthesis of the nanocarrier was verified by using zeta potential analysis, 1 H nuclear magnetic resonance and Fourier transform infrared spectra. Next, both in vitro and in vivo experiments were performed to evaluate the release behavior, cellular uptake, cytotoxicity, biodistribution and therapeutic efficacy of the nanoparticles. Our results showed FA–CS(VP-16)- g -PSBMA nanoparticles released VP-16 more effectively in acidic phosphate-buffered saline than that under neutral conditions, and could be effectively internalized into HeLa cells. Compared to the nanoparticles without FA, FA–CS(VP-16)- g -PSBMA nanoparticles exhibited a more significant inhibitory effect on HeLa cell viability in vitro . When HeLa tumor-bearing mice were intravenously administrated with fluorescence-labelled nanoparticles, FA-conjugated nanoparticles accumulated more rapidly at the tumor site. Furthermore, FA–CS(VP-16)- g -PSBMA nanoparticles demonstrated more superior therapeutic efficacy than VP-16. These results suggest that FA–CS- g -PSBMA nanoparticles represent a promising nanocarrier for anti-tumor drug delivery.